score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Investigate Actionability	FDA-Approved			Mutational Burden	High Mutational Burden								Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [>= 10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative traetment options.	Merck Sharp & Dohme Corp. Keytruda (pembrolizumab) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf. Revised October 2020. Accessed November 4, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125514s085lbl.pdf													0				 mutations per Mb		SC_9081		
Investigate Actionability		Clinical evidence		Somatic Variant	AR	Missense	p.H875Y	0.7704	196.0	0.0	0.0									Investigate Actionability	Abiraterone	Antiandrogen	Hormone therapy	Androgen receptor mutation may predict resistance to second generation androgen deprivation or direct androgen inhibitors.	Chen EJ, Sowalsky AG, Gao S, et al. Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors. Clin Cancer Res. 2015;21(6):1273-80.	https://doi.org/10.1158/1078-0432.CCR-14-1220						0	473.0	0.8055	1.0	AR p.H875Y (Missense)		SC_9081	SC_9081-TM	SC_9081-NB
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Frameshift	p.G643fs	0.3509	228.0	0.0	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	0.0	0.0	0.0	ASXL1 p.G643fs (Frameshift)		SC_9081	SC_9081-TM	SC_9081-NB
Investigate Actionability	FDA-Approved			Somatic Variant	RAD54L	Missense	p.R320W	0.0288	278.0	0.0	0.0		Investigate Actionability	Olaparib	PARP inhibition	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to olaparib for adult patients with deleterious or suspected deleterous germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.	AstraZeneca Pharmaceuticals, LP. Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration website. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf. Revised May 2020. Accessed 22 October, 2020.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208558s014lbl.pdf													0	52.0	0.0192	0.1019	RAD54L p.R320W (Missense)	0.0	SC_9081	SC_9081-TM	SC_9081-NB
Investigate Actionability	Clinical evidence			Somatic Variant	MSH2	Missense	p.S676P	0.7705	61.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients with defects in DNA mismatch repair genes may have enhanced sensitivity to immune checkpoint blockade.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596													0	153.0	0.9412	1.0	MSH2 p.S676P (Missense)		SC_9081	SC_9081-TM	SC_9081-NB
Investigate Actionability	Clinical evidence			Somatic Variant	FLCN	Missense	p.G235S	0.0229	262.0	1.6e-05	0.0		Investigate Actionability	Everolimus	PI3K/AKT/mTOR inhibition	Targeted therapy	Loss of function mutations in TSC1, TSC2, or FLCN may predict sensitivity to mTOR inhibition	Iyer G, Hanrahan AJ, Milowsky MI, et al. Genome sequencing identifies a basis for everolimus sensitivity. Science. 2012;338(6104):221.	https://doi.org/10.1126/science.1226344													0	100.0	0.03	0.2845	FLCN p.G235S (Missense)		SC_9081	SC_9081-TM	SC_9081-NB
Investigate Actionability	Inferential		Clinical evidence	Somatic Variant	POLD1	Frameshift	p.G114fs	0.3544	237.0	0.0	0.0		Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	Patients whose tumors contain DNA repair deficiencies may benefit from anti-PD-1 therapy. MMR deficient colorectal and noncolorectal cancer were enriched for partial response to Pembrolizumab in a cohort of 41 patients.	Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015;372(26):2509-20.	https://doi.org/10.1056/NEJMoa1500596								Investigate Actionability	0.0	A study of 529 patients with hereditary CRC were found to have an increased susceptibility to brain tumors.	Bellido F, Pineda M, Aiza G, et al. POLE and POLD1 mutations in 529 kindred with familial colorectal cancer and/or polyposis: review of reported cases and recommendations for genetic testing and surveillance. Genet Med. 2016;18(4):325-32.	https://doi.org/10.1038/gim.2015.75	0	0.0	0.0	0.0	POLD1 p.G114fs (Frameshift)		SC_9081	SC_9081-TM	SC_9081-NB
Investigate Actionability			Guideline	Somatic Variant	ASXL1	Missense	p.R499H	0.4134	462.0	2.5e-05	0.0																Investigate Actionability	0.0	Most frequent in Chronic Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	247.0	0.4251	1.0	ASXL1 p.R499H (Missense)		SC_9081	SC_9081-TM	SC_9081-NB
Investigate Actionability			Guideline	Somatic Variant	SF3B1	Splice Site	p.D907Y	0.4857	105.0	0.0	0.0																Investigate Actionability	1.0		National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	399.0	0.3434	1.0	SF3B1 p.D907Y (Splice Site)		SC_9081	SC_9081-TM	SC_9081-NB
Biologically Relevant				Somatic Variant	NF1	Missense	p.Y628C	0.4138	87.0	0.0	0.0																					0	53.0	0.3962	1.0	NF1 p.Y628C (Missense)		SC_9081	SC_9081-TM	SC_9081-NB
Biologically Relevant				Somatic Variant	RB1	Frameshift	p.R71fs	0.6197	71.0	0.0	0.0																					0	0.0	0.0	0.0	RB1 p.R71fs (Frameshift)		SC_9081	SC_9081-TM	SC_9081-NB
Biologically Relevant				Microsatellite Stability	Supporting variants		ACVR2A p.E93fs (Frameshift), ACVR2A p.K437fs (Frameshift), PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)																									0				Supporting variants: ACVR2A p.E93fs (Frameshift), ACVR2A p.K437fs (Frameshift), PRDM2 p.703_704insP (Insertion), MSH3 p.AAAAAA52del (Deletion), MSH3 p.PPA66del (Deletion)		SC_9081		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.603																									0				COSMIC Signature (version 2) 1 (60%)		SC_9081		
Biologically Relevant				Mutational Signature	COSMIC Signature 6	version 2	0.397																									0				COSMIC Signature (version 2) 6 (40%)		SC_9081		
